Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Gujarat Terce Laboratories Limited specializes in the production of generic pharmaceuticals, primarily focusing on formulations for chronic diseases. With a strong presence in the Indian market and exports to over 20 countries, the company leverages its low-cost manufacturing capabilities and regulatory compliance to maintain a competitive edge.
Gujarat Terce generates revenue through the sale of generic drugs, which are priced competitively due to low production costs. The company benefits from economies of scale and a robust supply chain, allowing it to maintain a gross margin of 29.2%. Its strong R&D capabilities enable the development of new formulations, enhancing its product portfolio.
Regulatory approvals for new drug formulations
Changes in pricing regulations in key markets like India
Fluctuations in raw material costs, particularly for APIs
Market share gains in export markets
Regulatory changes that could impact pricing and reimbursement policies
Technological advancements in drug development that could outpace current capabilities
Intensifying competition from both domestic and international generic manufacturers
Potential market entry of large pharmaceutical companies into the generic space
Limited liquidity due to low operating cash flow
Potential for increased costs if raw material prices rise significantly
moderate - As a pharmaceutical company, Gujarat Terce's revenues are somewhat insulated from economic downturns, but consumer spending on healthcare can be affected by GDP fluctuations.
Low - The company's low debt levels mean that rising interest rates have minimal impact on financing costs, but they could affect consumer spending indirectly.
minimal - The company operates with a low debt-to-equity ratio, reducing its reliance on credit markets.
value - The company's low price-to-sales ratio of 0.7x may attract value investors looking for undervalued stocks in the pharmaceutical sector.
moderate - The stock has experienced a 1-year return of -14.8%, indicating some volatility in market perception.